Ind-Swift Labs Investor Presentation: Q3 FY26 Results & Strategic Growth
Ind-Swift Labs reported Q3 FY26 revenue of ₹177.06 Cr, with a 22.6% rise in PAT to ₹10.74 Cr. The company completed a ₹1,650 Cr divestment of its API & CRAMS business, becoming net debt-free. It targets doubling revenue by FY29 and aims for significant growth from CDMO and own-brand segments.
The divestment of a major business segment and the stated strategy for future growth, including revenue targets and margin expansion, have a significant impact on the company's financial outlook and strategic direction.
The company reported improved profitability metrics, a significant strategic divestment that resulted in a debt-free status, and clear future growth strategies with targeted revenue expansion.
Ind-Swift Laboratories Limited has presented its investor presentation for the un-audited financial results for the quarter ended December 31, 2025.
The company reported stable revenue for Q3 FY26, with a 6.60% increase in Operating EBITDA and a 48 BPS expansion in Operating EBITDA margin, driven by reduced raw material and employee benefit expenses. Net Profit (PAT) saw a 22.60% rise quarter-over-quarter.
A significant strategic move includes the ₹1,650 Cr divestment of the API & CRAMS business to Synthimed Labs, making Ind-Swift Laboratories a Net Debt Free entity. This divestment, combined with the merger of Ind-Swift Limited into ISLL, has repositioned the company as a Pure-Play Formulations Platform with a revenue base of ₹550 Cr, primarily from exports.
The company is focusing on high-growth engines, including strengthening its CDMO visibility through a FY27 accretive Viatris partnership and expanding its Own-Brand footprint in UAE and Central Asia with over 400 registered products. With high-margin segments like Ethical (76% GM), Own-Brand (51% GM), and CMO (42% GM), Ind-Swift Laboratories targets to double its revenue by FY29 while ensuring consistent profitability.
The presentation also detailed the company's strategic evolution, growth milestones, transaction summary of the API & CRAMS divestment, and a post-transformation overview highlighting its new operating model with domestic and global business units. The company has a strong R&D focus, with over 1915 dossiers filed and 520+ global approvals. Future regulatory targets include inspections for Saudi FDA and Taiwan FDA in 2025.
Financial highlights for Q3 FY26 show Total Revenue at ₹177.06 Cr, Operating EBITDA at ₹9.11 Cr with a 5.95% margin, and PAT at ₹10.74 Cr with a 6.07% margin. For the 9 months ended FY26, Total Revenue was ₹507.93 Cr, Operating EBITDA was ₹26.09 Cr (5.63% margin), and PAT was ₹27.62 Cr (5.44% margin).
The company projects a topline CAGR of 20-25%, scaling from ₹550 Cr to ₹1,200+ Cr by FY29. CDMO revenue is expected to triple over four years, and EBITDA margins are projected to expand by 250-300 BPS. Key strategic growth triggers include the Viatris commercialization in FY27, expected to bring ₹200-220 Cr in incremental revenue, and greenfield expansion in UAE, Uzbekistan, and West Africa.
What to do with a filing like this
Ind-Swift Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Ind-Swift Laboratories Limited. Read the original for the full detail.